{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:05:47Z","timestamp":1740128747126,"version":"3.37.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"Supplement_7","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["W911QY20C0099"],"award-info":[{"award-number":["W911QY20C0099"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Health and Human Services"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI142785"],"award-info":[{"award-number":["U19AI142785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Marburg virus (MARV) causes a hemorrhagic fever disease in human and nonhuman primates with high levels of morbidity and mortality. Concerns about weaponization of aerosolized MARV have spurred the development of nonhuman primate (NHP) models of aerosol exposure. To address the potential threat of aerosol exposure, a monoclonal antibody that binds MARV glycoprotein was tested, MR186YTE, for its efficacy as a prophylactic. MR186YTE was administered intramuscularly to NHPs at 15 or 5 mg\/kg 1 month prior to MARV aerosol challenge. Seventy-five percent (3\/4) of the 15 mg\/kg dose group and 50% (2\/4) of the 5 mg\/kg dose group survived. Serum analyses showed that the NHP dosed with 15 mg\/kg that succumbed to infection developed an antidrug antibody response and therefore had no detectable MR186YTE at the time of challenge. These results suggest that intramuscular dosing of mAbs may be a clinically useful prophylaxis for MARV aerosol exposure.<\/jats:p>","DOI":"10.1093\/infdis\/jiad278","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:52:26Z","timestamp":1689900746000},"page":"S701-S711","source":"Crossref","is-referenced-by-count":1,"title":["Long-term Prophylaxis Against Aerosolized Marburg Virus in Nonhuman Primates With an Afucosylated Monoclonal Antibody"],"prefix":"10.1093","volume":"228","author":[{"given":"Dafna","family":"Abelson","sequence":"first","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Barajas","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Stuart","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do","family":"Kim","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arumugapradeep","family":"Marimuthu","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Hu","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Ailor","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J","family":"Whaley","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Vu","sequence":"additional","affiliation":[{"name":"Integrated Biotherapeutics , Rockville, Maryland , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystle N","family":"Agans","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J","family":"Deer","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie S","family":"Dobias","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Woolsey","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek N","family":"Prasad","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E","family":"Peel","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William S","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W","family":"Cross","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W","family":"Geisbert","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla A","family":"Fenton","sequence":"additional","affiliation":[{"name":"Galveston National Laboratory, University of Texas Medical Branch , Galveston, Texas , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Zeitlin","sequence":"additional","affiliation":[{"name":"Mapp Biopharmaceutical, Inc , San Diego, California , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"2024072000014558300_jiad278-B1","first-page":"923","volume-title":"Fields virology","author":"Feldmann","year":"2013"},{"author":"Centers for Disease Control and Prevention","key":"2024072000014558300_jiad278-B2"},{"key":"2024072000014558300_jiad278-B3","doi-asserted-by":"crossref","DOI":"10.5962\/bhl.title.29160","volume-title":"Die geschichte der Diphtherie (mit besonderer Ber\u00fccksichtigung der Immunit\u00e4tslehre)","author":"Behring","year":"1893"},{"key":"2024072000014558300_jiad278-B4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1286-4579(00)00355-5","article-title":"Preventing infectious disease with passive immunization","volume":"2","author":"Zeitlin","year":"2000","journal-title":"Microbes Infect"},{"key":"2024072000014558300_jiad278-B5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3201\/eid0501.990107","article-title":"Using monoclonal antibodies to prevent mucosal transmission of epidemic infectious diseases","volume":"5","author":"Zeitlin","year":"1999","journal-title":"Emerging Infect Dis"},{"key":"2024072000014558300_jiad278-B6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/clinids\/21.1.150","article-title":"Return to the past: the case for antibody-based therapies in infectious diseases","volume":"21","author":"Casadevall","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2024072000014558300_jiad278-B7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/14712590802610692","article-title":"Palivizumab: where to from here?","volume":"9","author":"Georgescu","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"2024072000014558300_jiad278-B8","doi-asserted-by":"crossref","first-page":"eaai8711","DOI":"10.1126\/scitranslmed.aai8711","article-title":"Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody","volume":"9","author":"Mire","year":"2017","journal-title":"Sci Transl Med"},{"key":"2024072000014558300_jiad278-B9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","article-title":"Mechanism of human antibody-mediated neutralization of Marburg virus","volume":"160","author":"Flyak","year":"2015","journal-title":"Cell"},{"key":"2024072000014558300_jiad278-B10","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"2024072000014558300_jiad278-B11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/antib8040055","article-title":"Antibody structure and function: the basis for engineering therapeutics","volume":"8","author":"Chiu","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"2024072000014558300_jiad278-B12","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.molmed.2016.09.002","article-title":"Modulating antibody functionality in infectious disease and vaccination","volume":"22","author":"Gunn","year":"2016","journal-title":"Trends Mol Med"},{"key":"2024072000014558300_jiad278-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.1976580","article-title":"Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection","volume":"17","author":"Gunn","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2024072000014558300_jiad278-B14","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1073\/pnas.1402458111","article-title":"Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy","volume":"111","author":"Hiatt","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024072000014558300_jiad278-B15","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024072000014558300_jiad278-B16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/INF.0000000000001916","article-title":"Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants","volume":"37","author":"Domachowske","year":"2018","journal-title":"Pediatric Infect Dis J"},{"key":"2024072000014558300_jiad278-B17","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"2024072000014558300_jiad278-B18","doi-asserted-by":"crossref","first-page":"e01714-16","DOI":"10.1128\/AAC.01714-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults","volume":"61","author":"Griffin","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024072000014558300_jiad278-B19","doi-asserted-by":"crossref","first-page":"e01020-16","DOI":"10.1128\/AAC.01020-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults","volume":"61","author":"Yu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024072000014558300_jiad278-B20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.chom.2018.12.005","article-title":"A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates","volume":"25","author":"Bornholdt","year":"2019","journal-title":"Cell Host Microbe"},{"key":"2024072000014558300_jiad278-B21","doi-asserted-by":"crossref","first-page":"e00747-19","DOI":"10.1128\/AEM.00747-19","article-title":"A vibrating mesh nebulizer as an alternative to the Collison three-jet nebulizer for infectious disease aerobiology","volume":"85","author":"Bowling","year":"2019","journal-title":"Appl Environ Microbiol"},{"key":"2024072000014558300_jiad278-B22","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/v14030639","article-title":"Characterisation of particle size and viability of SARS-CoV-2 aerosols from a range of nebuliser types using a novel sampling technique","volume":"14","author":"Paton","year":"2022","journal-title":"Viruses"},{"key":"2024072000014558300_jiad278-B23","doi-asserted-by":"crossref","first-page":"847","DOI":"10.4161\/viru.27172","article-title":"Particle size and pathogenicity in the respiratory tract","volume":"4","author":"Thomas","year":"2013","journal-title":"Virulence"},{"key":"2024072000014558300_jiad278-B24","doi-asserted-by":"crossref","first-page":"e0005532","DOI":"10.1371\/journal.pntd.0005532","article-title":"Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus","volume":"11","author":"Cong","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"2024072000014558300_jiad278-B25","doi-asserted-by":"crossref","first-page":"e0006978","DOI":"10.1371\/journal.pntd.0006978","article-title":"Aerosol exposure to intermediate size Nipah virus particles induces neurological disease in African green monkeys","volume":"12","author":"Hammoud","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"2024072000014558300_jiad278-B26","doi-asserted-by":"crossref","first-page":"S582","DOI":"10.1093\/infdis\/jiy293","article-title":"Postexposure efficacy of recombinant vesicular stomatitis virus vectors against high and low doses of Marburg virus variant Angola in nonhuman primates","volume":"218","author":"Woolsey","year":"2018","journal-title":"J Infect Dis"},{"key":"2024072000014558300_jiad278-B27","doi-asserted-by":"crossref","first-page":"250ra116","DOI":"10.1126\/scitranslmed.3009706","article-title":"Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA","volume":"6","author":"Thi","year":"2014","journal-title":"Sci Transl Med"},{"key":"2024072000014558300_jiad278-B28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0300985813485099","article-title":"Principles for valid histopathologic scoring in research","volume":"50","author":"Gibson-Corley","year":"2013","journal-title":"Vet Pathol"},{"key":"2024072000014558300_jiad278-B29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","article-title":"Neonatal Fc receptor and IgG-based therapeutics","volume":"3","author":"Kuo","year":"2011","journal-title":"mAbs"},{"key":"2024072000014558300_jiad278-B30","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3390\/vaccines10081314","article-title":"Development of a well-characterized cynomolgus macaque model of Marburg virus disease for support of vaccine and therapy development","volume":"10","author":"Alfson","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2024072000014558300_jiad278-B31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/v8040087","article-title":"Natural history of aerosol exposure with Marburg virus in rhesus macaques","volume":"8","author":"Ewers","year":"2016","journal-title":"Viruses"},{"key":"2024072000014558300_jiad278-B32","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0300985810378597","article-title":"Aerosol exposure to the Angola strain of Marburg virus causes lethal viral hemorrhagic fever in cynomolgus macaques","volume":"47","author":"Alves","year":"2010","journal-title":"Vet Pathol"},{"key":"2024072000014558300_jiad278-B33","doi-asserted-by":"crossref","first-page":"e0138843","DOI":"10.1371\/journal.pone.0138843","article-title":"Dose response of MARV\/Angola infection in cynomolgus macaques following IM or aerosol exposure","volume":"10","author":"Johnston","year":"2015","journal-title":"PLoS One"},{"key":"2024072000014558300_jiad278-B34","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.1128\/JVI.01147-15","article-title":"Temporal characterization of Marburg virus Angola infection following aerosol challenge in rhesus macaques","volume":"89","author":"Lin","year":"2015","journal-title":"J Virol"},{"key":"2024072000014558300_jiad278-B35","doi-asserted-by":"crossref","first-page":"e0212649","DOI":"10.1371\/journal.pone.0212649","article-title":"Introduction of the YTE mutation into the non-immunogenic HIV bnAb PGT121 induces anti-drug antibodies in macaques","volume":"14","author":"Rosenberg","year":"2019","journal-title":"PLoS One"},{"key":"2024072000014558300_jiad278-B36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1126\/science.aai8128","article-title":"Igg antibodies to dengue enhanced for FcgammaRIIIA binding determine disease severity","volume":"355","author":"Wang","year":"2017","journal-title":"Science"},{"key":"2024072000014558300_jiad278-B37","doi-asserted-by":"crossref","first-page":"eabm7853","DOI":"10.1126\/scitranslmed.abm7853","article-title":"Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Sci Transl Med"},{"key":"2024072000014558300_jiad278-B38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.it.2022.08.001","article-title":"Afucosylated IgG responses in humans\u2014structural clues to the regulation of humoral immunity","volume":"43","author":"Oosterhoff","year":"2022","journal-title":"Trends Immunol"},{"key":"2024072000014558300_jiad278-B39","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"2024072000014558300_jiad278-B40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/514115","article-title":"Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus","volume":"176","author":"Johnson","year":"1997","journal-title":"J Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad278\/50920059\/jiad278.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S701\/57219375\/jiad278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/228\/Supplement_7\/S701\/57219375\/jiad278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T02:17:41Z","timestamp":1721441861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/228\/Supplement_7\/S701\/7227269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":40,"journal-issue":{"issue":"Supplement_7","published-online":{"date-parts":[[2023,7,20]]},"published-print":{"date-parts":[[2023,11,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad278","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2023,11,15]]},"published":{"date-parts":[[2023,7,20]]}}}